Jpmorgan Chase & CO Centessa Pharmaceuticals PLC Transaction History

Jpmorgan Chase & CO

$1.22 Trillion
Q3 2024

A detailed history of Jpmorgan Chase & CO transactions in Centessa Pharmaceuticals PLC stock. As of the latest transaction made, Jpmorgan Chase & CO holds 135,903 shares of CNTA stock, worth $2.3 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

135,903

Previous 6,568 1969.17%

Holding current value

$2.3 Million

Previous $59,000 3583.05%

% of portfolio

0.0%

Previous 0.0%

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Dec 26, 2024	BUY	$8.58 - $16.99 $1.11 Million - $2.2 Million	129,335 Added 1969.17%	135,903 $2.17 Million
Q3 2024 Nov 08, 2024	BUY	$8.58 - $16.99 $1.11 Million - $2.2 Million	129,335 Added 1969.17%	135,903 $2.17 Million
Q2 2024 Dec 26, 2024	SELL	$8.04 - $11.87 $1.04 Million - $1.54 Million	-129,335 Reduced 95.17%	6,568 $59,000
Q2 2024 Aug 12, 2024	SELL	$8.04 - $11.87 $166,403 - $245,673	-20,697 Reduced 75.91%	6,568 $59,000
Q1 2024 Dec 26, 2024	SELL	$6.73 - $12.2 $731,133 - $1.33 Million	-108,638 Reduced 79.94%	27,265 $308,000
Q1 2024 May 10, 2024	BUY	$6.73 - $12.2 $111,953 - $202,947	16,635 Added 156.49%	27,265 $308,000
Q4 2023 Dec 26, 2024	SELL	$5.52 - $8.03 $691,506 - $1.01 Million	-125,273 Reduced 92.18%	10,630 $84,000
Q4 2023 Feb 12, 2024	BUY	$5.52 - $8.03 $2,920 - $4,247	529 Added 5.24%	10,630 $84,000
Q3 2023 Nov 14, 2023	SELL	$6.01 - $8.24 $296,070 - $405,927	-49,263 Reduced 82.98%	10,101 $65,000
Q2 2023 Aug 11, 2023	SELL	$3.68 - $6.9 $146,688 - $275,040	-39,861 Reduced 40.17%	59,364 $367,000
Q1 2023 May 11, 2023	BUY	$3.03 - $4.0 $262,028 - $345,912	86,478 Added 678.42%	99,225 $382,000
Q4 2022 Feb 13, 2023	BUY	$3.05 - $4.19 $28,535 - $39,201	9,356 Added 275.91%	12,747 $39,000
Q3 2022 Nov 14, 2022	SELL	$3.8 - $5.91 $665,087 - $1.03 Million	-175,023 Reduced 98.1%	3,391 $14,000
Q2 2022 Aug 11, 2022	BUY	$3.18 - $9.85 $552,359 - $1.71 Million	173,698 Added 3683.16%	178,414 $869,000
Q1 2022 May 11, 2022	BUY	$7.45 - $11.59 $1,542 - $2,399	207 Added 4.59%	4,716 $42,000
Q4 2021 Feb 10, 2022	BUY	$10.99 - $17.54 $29,464 - $47,024	2,681 Added 146.66%	4,509 $51,000
Q3 2021 Nov 12, 2021	BUY	$16.7 - $23.11 $30,527 - $42,245	1,828 New	1,828 $30,000

Others Institutions Holding CNTA

# of Institutions

106

Shares Held

118M

Call Options Held

5.9K

Put Options Held

53K

View Full List

About Centessa Pharmaceuticals plc

Ticker CNTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 94,339,296
Market Cap $1.6B
Description
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase III clinical development for the treatment of autosomal dominant polycystic kidney disease; an...

More about CNTA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account

Jpmorgan Chase & CO Centessa Pharmaceuticals PLC Transaction History